What the trial was testing
The HOPE-B enrolled 67 patients with hemophilia. The study was sponsored by CSL Behring and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Bleeding episodes dropped from 4.19 per year to 1.51 per year after a single gene therapy infusion.
The New England journal of medicine · 2023 · NCT03569891
These findings — that patients had 64% fewer bleeding episodes after gene therapy vs. preventive injections — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 67 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with hemophilia, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This gene therapy is FDA-approved and available now under the brand name Hemgenix. If you have hemophilia B and are considering it, talk to your hematologist about whether you're a candidate — it worked well in this large study and could free you from daily or weekly injections. The one-time infusion raised clotting factor levels and reduced bleeds by nearly two-thirds over 18 months.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open hemophilia trials
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
A non-randomized, open-label study to evaluate the safety, kinetics and efficacy of a single intravenous infusion of ZS801 in hemophilia B subjects with endogenous FIX ≤2%.
Tight Control of Treatment Adherence and Efficacy by Telemedicine for an Improved Personalized Management of Patients With Hemophilia
In patients with haemophilia, close monitoring of bleeding with optimal adherence to treatment, a personalised treatment programme and the possibility of early diagnosis of haemarthrosis are essential. The TEMPO project will help advance the state of the art in optimal adherence, rigorous monitoring, and accurate and early diagnosis and management of haemarthrosis by collecting and integrating big data in order to personalise the treatment regimen for each patient, as envisaged by the current model of personalised medicine.